Suppr超能文献

阿尔茨海默病严重程度对脑脊液去甲肾上腺素浓度的影响。

Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration.

作者信息

Elrod R, Peskind E R, DiGiacomo L, Brodkin K I, Veith R C, Raskind M A

机构信息

Psychiatry Service, VA Puget Sound Health Care System, Seattle, WA 98108, USA.

出版信息

Am J Psychiatry. 1997 Jan;154(1):25-30. doi: 10.1176/ajp.154.1.25.

Abstract

OBJECTIVE

Although loss of noradrenergic neurons in the locus ceruleus has been consistently demonstrated postmortem in Alzheimer's disease, several small studies suggest that indices of central noradrenergic activity increase with the severity of Alzheimer's disease in living patients. The authors estimated the effect of Alzheimer's disease severity on central noradrenergic activity by comparing the CSF norepinephrine concentrations of subjects with Alzheimer's disease in earlier and advanced stages. The effect of normal aging on CSF norepinephrine also was determined.

METHOD

Lumbar punctures were performed in 49 subjects with Alzheimer's disease of mild or moderate severity, 25 subjects with advanced Alzheimer's disease, 42 normal older subjects, and 54 normal young subjects. Advanced Alzheimer's disease was defined prospectively by a Mini-Mental State score of less than 12. Norepinephrine was measured by radioenzymatic assay.

RESULTS

CSF norepinephrine concentration was significantly higher in the patients with advanced Alzheimer's disease (mean = 279 pg/ml, SD = 122) than in those with mild to moderate severity (mean = 198 pg/ml, SD = 89), normal older subjects (mean = 219 pg/ml, SD = 88), or normal young subjects (mean = 154 pg/ml, SD = 53). CSF and plasma norepinephrine levels and mean arterial blood pressure all were higher in the older subjects than in the young subjects.

CONCLUSIONS

Despite the loss of locus ceruleus neurons in Alzheimer's disease, the aging-associated high concentration of CSF norepinephrine is retained in the earlier stages of Alzheimer's disease and increases further as the disease progresses. Increased brain noradrenergic activity may contribute to the agitated behaviors or cognitive deficits of patients with advanced Alzheimer's disease.

摘要

目的

尽管在阿尔茨海默病患者死后尸检中一直证实蓝斑去甲肾上腺素能神经元缺失,但几项小型研究表明,在活着的患者中,中枢去甲肾上腺素能活动指标会随着阿尔茨海默病病情的加重而增加。作者通过比较早期和晚期阿尔茨海默病患者脑脊液中去甲肾上腺素的浓度,评估了阿尔茨海默病严重程度对中枢去甲肾上腺素能活动的影响。同时也确定了正常衰老对脑脊液去甲肾上腺素的影响。

方法

对49例轻度或中度阿尔茨海默病患者、25例晚期阿尔茨海默病患者、42例正常老年受试者和54例正常年轻受试者进行腰椎穿刺。晚期阿尔茨海默病通过简易精神状态评分低于12分进行前瞻性定义。采用放射酶法测定去甲肾上腺素。

结果

晚期阿尔茨海默病患者脑脊液去甲肾上腺素浓度(均值 = 279 pg/ml,标准差 = 122)显著高于轻度至中度患者(均值 = 198 pg/ml,标准差 = 89)、正常老年受试者(均值 = 219 pg/ml,标准差 = 88)或正常年轻受试者(均值 = 154 pg/ml,标准差 = 53)。老年受试者的脑脊液和血浆去甲肾上腺素水平以及平均动脉血压均高于年轻受试者。

结论

尽管阿尔茨海默病患者存在蓝斑神经元缺失,但与衰老相关的脑脊液去甲肾上腺素高浓度在阿尔茨海默病早期得以保留,并随着疾病进展进一步升高。脑去甲肾上腺素能活动增加可能导致晚期阿尔茨海默病患者出现激越行为或认知缺陷。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验